Newsfeeds - Spark Newswire

1 minute read

AbCellera Reports Balanivimab, Estesevimab Authorized As Antibody Therapy For Emergency Use In COVID-19 Patients Under Age 12

Today, 5:15 PM

AbCellera (NASDAQ:ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include pediatric patients

ABCL

1 minute read

AbCellera Biologics Q3 EPS $(0.08) Down From $(0.02) YoY, Sales $5.51M Down From $9.36M YoY

By Benzinga Newsdesk

Today, 5:15 PM

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.08) per share. This is a 300 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $5.51 million in

ABCL

1 minute read

AbCellera Biologics Q3 EPS $(0.02) Beats $(0.03) Estimate, Sales $9.36M Up From $5.51M YoY

By Benzinga Newsdesk

Today, 5:15 PM

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported $9.36 million in sales this quarter. This is a

ABCL

2 minute read

Earnings

How Bad Are AbCellera Biologics’s Earnings? | Return On Capital Employed

By Benzinga Insights

Today, 5:15 PM

Benzinga Pro data, AbCellera Biologics (NASDAQ:ABCL) reported Q2 sales of $27.64 million. Earnings fell to a loss of $7.03 million, resulting in a 104.45% decrease from last quarter.

ABCL

21 minute read

Earnings Scheduled For November 9, 2021

By Benzinga Insights

Today, 5:15 PM

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.

AAIC

4 minute read

The Daily Biotech Pulse: Restricted Authorization For Pfizer’s COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data

By Shanthi Rexaline

Today, 5:15 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)

ABCL

1 minute read

Cramer’s Advice On Ulta Beauty, Laredo Petroleum And More

By Craig Jones

Today, 5:15 PM

On CNBC's "Mad Money Lightning Round," Jim Cramer advised a viewer to buy more Ulta Beauty Inc (NASDAQ: ULTA). He likes the stock very much.

ABCL

2 minute read

News

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies; No Terms Disclosed

By Michael Horton

Today, 5:15 PM

AbCellera (NASDAQ:ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement to discover

ABCL

2 minute read

Lilly To Supply EU, EEA With Up To 220,000 Doses Of AbCellera-Discovered Bamlanivimab Together With Etesevimab For Treatment Of Confirmed COVID-19

By Benzinga Newsdesk

Today, 5:15 PM

AbCellera (NASDAQ:ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with

ABCL